Deeptech funding, the structuring of investment and the expansion of digital health initiatives point to an ecosystem in transition, with potential complementarities with Germany’s life sciences landscape.
Over the past months, Madrid has seen several converging signals across the life sciences value chain, particularly on the technology side.
Deeptech and scientific computing: strategic convergence
In February 2026, Spanish biotech company Pharmacelera raised €6 million to accelerate the development of its high-performance computing platform for drug discovery. This positioning echoes trends observed in Germany, where AI-driven drug discovery, molecular modelling and advanced computing are already key areas of activity, particularly in regions such as Bavaria, Baden-Württemberg and North Rhine-Westphalia. Complementarity may emerge from the combination of Germany’s industrial capabilities and Spain’s growing technology platforms.
Structuring life sciences investment: co-development opportunities
Recent strengthening of specialised investment vehicles targeting medical technologies and biotech — representing several hundred million euros under management — reflects a maturing life sciences financing environment in Spain. For German funds and scale-ups, these developments may create opportunities for co-investment, capital partnerships and joint European structuring strategies.
Digital health: an experimentation environment
Madrid is also developing initiatives that bring together startups, hospitals and public stakeholders around healthcare digital transformation. Key segments include clinical data, remote monitoring, applied artificial intelligence and decision-support tools, areas where many German companies have strong technological expertise but are often seeking agile European pilot environments.
Industrial reference point
The investment announced in 2025 by Eli Lilly at its Alcobendas site remains an important industrial reference. More recent developments, however, highlight the territory’s momentum in technology-driven and entrepreneurial segments.
Strategic perspective for German companies
For German life sciences stakeholders, Madrid can be read as:
- A complementary environment for deeptech projects.
- A gateway to the Iberian and Southern European markets.
- A framework conducive to digital health pilots.
- An ecosystem in consolidation, still open to structuring partnerships.
In a context of growing European competition in biotech and digital health, these signals suggest that Madrid is increasingly relevant in cross-border expansion and cooperation strategies.